Skip to main content
. 2015 Jun 26;12:15. doi: 10.1186/s12987-015-0010-1

Table 1.

Clinical background of study population

Control iNPH P value
Number 9 20
Male preponderance, N (%) 6 (66.7) 12 (60) 0.7308
Age 74.2 ± 7.9 76.1 ± 6.4 0.6869
History
 Hypertension 5 11 0.9778
 Diabetes mellitus 0 2 0.2128
 Hyperlipidemia 3 6 0.858
 Anti-coagulant/platelet drugs 1 8 0.0988
 Lacunar stroke 1 2 0.928
 Alzheimer’s disease 0 3 0.1417
 Chronic kidney disease 0 1 0.0713
 Chronic obstructive pulmonary disease 0 1 0.0713
Activity of daily life
 Modified Rankin scale (G2, 3, 4)/(G0–4) (%) 0 95 <0.0001*
Symptoms (iNPHGS)
 Gait disturbance (G2–4)/(G0–4) (%) 0 85 <0.0001*
 Cognition disturbance (G2–4)/(G0–4) (%) 0 85 <0.0001*
 Urination disturbance (G2–4)/(G0–4) (%) 0 75 0.0009*
Tap test
 TUG (baseline) (s) NA 35.0 ± 47.7
 TUG (% change) NA 25.6 ± 34.6
 MMSE (baseline score) NA 21.4 ± 5.9
 MMSE (difference) NA 3.1 ± 2.9
Shunt surgery, N 0 12

G grade, iNPHGS iNPH grading scale, MMSE minimental state examination, NA not assessed, TUG timed up and go test.

* Statistically significant.